| Literature DB >> 32521288 |
Jie Yang1, Xin He2, Zhen Ke3, Jianjiao Chen3, Zhenyuan Zou3, Bo Wei4, Dengfeng Zou5, Jianhua Zou6.
Abstract
Ru (II) compounds have potential application in photodynamic therapy (PDT). In the current study, two Ru (II) compounds based on the auxiliary ligand 2,2'-bipyridine (bipy) by changing main ligands 5-(2-pyridyl) tetrazole (Hpytz) and di(2H-tetrazol-5-yl) amine (H2datz) have been successfully synthesized and characterized, [Ru (pytz)(bipy)2][PF6] (1) and [Ru(Hdatz)(bipy)2][PF6] (2). These compounds can form nanoparticles (NPs) by nano-precipitation. And [Ru(pytz)(bipy)2][PF6] NPs with a lower half maximal inhibitory concentration (IC50) of 37 μg/mL on HeLa cells than that of [Ru(Hdatz)(bipy)2][PF6] NPs (65 μg/mL). Meanwhile, negligible dark toxicity has been also observed for these NPs even under high concentrations. The results show that [Ru(pytz)(bipy)2][PF6] (1) and [Ru(Hdatz)(bipy)2][PF6] (2) NPs can inhibit cell proliferation in vitro, and may be potential candidates for photodynamic therapy.Entities:
Keywords: HeLa; Photodynamic therapy; Ru(II); Tetrazole
Mesh:
Substances:
Year: 2020 PMID: 32521288 DOI: 10.1016/j.jinorgbio.2020.111127
Source DB: PubMed Journal: J Inorg Biochem ISSN: 0162-0134 Impact factor: 4.155